Therapeutic developments for multidrug-resistant tuberculosis
Hongfei Duan
Department of Tuberculosis,Beijing Tuberculosis&Thoracic Tumor Research Institute/Beijing Chest Hospital,Capital Medical University,Beijing,China
摘要：Tuberculosis(TB)remains the leading infectious disease globally,with 1.25 million deaths and 10.8 million new cases in 2023,including 400,000 rifampin-resistant/multidrug-resistant TB(RR/MDR-TB)cases.RR/MDR-TB accounts for 15–20%of TB-related deaths and poses significant economic and treatment challenges due to low cure rates(68%)and high costs.The heterogeneity of Mycobacterium tuberculosis infections com-plicates therapy,requiring prolonged regimens and multidrug combinations.Advances in treatment include re-purposed antibiotics(e.g.,linezolid),re-engineered oxazolidinones(e.g.,sutezolid),and improved bedaquiline analogues addressing resistance and toxicity.Future strategies emphasize shorter,accessible regimens,reliable drug susceptibility testing(DST),and effective management of treatment failures.Targeted next-generation se-quencing(tNGS)has improved resistance detection but remains limited for some second-line drugs.Phenotypic DST is still indispensable.Clinicians must address emerging drug resistance and develop salvage regimens while reducing disease transmission through public health measures.These approaches are critical to improving RR/MDR-TB outcomes globally.
机标关键词：resistantdevelopmentsmultidrugtherapeutictuberculosis
论文发表日期：2024-12-30
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：11( 2-12 )
英文信息